Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
3.750
+0.150 (4.17%)
At close: Aug 29, 2025, 4:00 PM
3.690
-0.060 (-1.60%)
After-hours: Aug 29, 2025, 4:10 PM EDT
Molecular Partners AG Revenue
Molecular Partners AG had revenue of 681.00K CHF in the twelve months ending June 30, 2025, down -91.34% year-over-year. In the year 2024, Molecular Partners AG had annual revenue of 4.97M, down -29.38%.
Revenue (ttm)
681.00K CHF
Revenue Growth
-91.34%
P/S Ratio
158.29
Revenue / Employee
4,297 CHF
Employees
159
Market Cap
135.54M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MOLN News
- 4 days ago - EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 5 days ago - Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025 - GlobeNewsWire
- 2 months ago - Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 - GlobeNewsWire
- 2 months ago - Molecular Partners to cut workforce by a quarter - Reuters
- 2 months ago - Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway - GlobeNewsWire
- 3 months ago - Molecular Partners to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025 - GlobeNewsWire
- 4 months ago - Molecular Partners Announces all Board Proposals Approved at Annual General Meeting - GlobeNewsWire